Drugmaker Elan sells EDT unit to Alkermes for $960 million

the company would more than recoup that within 12 months due to strong sales growth from its key multiple sclerosis drug, Tysabri. "The biotech business on a standalone basis we still see as growing strong double digit growth on revenue and the same on...